Sanuwave is pleased to announce preliminary revenues of $13.3 million to $13.4 million for the fourth quarter ended December 31, 2025. This represents the highest quarterly revenues in Company history.
Q4 2025 revenue increased between 29% and 30% compared to Q4 2024.
Full Year 2025 revenue increased to $44.3-$44.4 million up 36% vs Full Year 2024. 2025 annual revenues were an all-time record for the Company.
EDEN PRAIRIE, Minn., Jan. 09, 2026 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ:SNWV), a leading provider of FDA-approved directed energy systems used in advanced wound care, today announced that revenues for the fourth quarter of 2025 are expected to be in the range of $13.3 to $13.4 million, an increase of 29% to 30% over Q4 2024. This number is within the range of guidance given in the Company’s Q3 2025 earnings release issued on November 7, 2025.
“We’re pleased to once more be on guidance and on track for Q4 and for full year 2025,” said CEO Morgan Frank. “As we discussed when releasing Q3, the second half of 2025 was a time of …